Search results for "interleukin"

showing 10 items of 1856 documents

Acute inflammatory response after inguinal and incisional hernia repair with implantation of polypropylene mesh of different size.

2005

The purpose of this study was to assess the modifications of interleukin (IL)-6, C-reactive protein (CRP), leukocytes and fibrinogen after implantation of polypropylene mesh.Thirty-six patients were included in this study and divided into two groups. To the first group were allocated patients affected by inguinal hernia and undergoing conventional repair (subgroup Ia) or hernioplasty with 40-cm(2) polypropylene mesh (subgroup Ib). To the second group were allocated patients affected by incisional hernia and undergoing conventional repair (subgroup IIa) or incisional hernia repair with 400-cm(2) polypropylene mesh (subgroup IIb). Peripheral venous blood samples were collected 24 h before sur…

medicine.medical_specialtyIncisional herniaBiocompatible MaterialsHernia InguinalFibrinogenPolypropylenesProsthesis ImplantationmedicineLeukocytesHumansHerniaHerniorrhaphyInflammationbiologybusiness.industryInterleukin-6C-reactive proteinFibrinogenVenous bloodMiddle AgedSurgical Meshmedicine.diseaseSurgeryHernia AbdominalInguinal herniaSurgical meshC-Reactive Proteinbiology.proteinSurgeryFemalebusinessAbdominal surgerymedicine.drugLangenbeck's archives of surgery
researchProduct

Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism

2007

Acetylcholine may play a role in cell activation and airway inflammation. We evaluated the levels of both mRNA and protein of muscarinic M(1), M(2), M(3) receptors in human bronchial epithelial cell line (16HBE). 16HBE cells were also stimulated with acetylcholine and extracellular signal-regulated kinase1/2 (ERK1/2) and NFkB pathway activation as well as the IL-8 release was assessed in the presence or absence of the inhibitor of Protein-kinase (PKC) (GF109203X), of the inhibitor of mitogenic activated protein-kinase kinase (MAPKK) (PDO9805), of the inhibitor of kinaseB-alpha phosphorilation (pIkBalpha) (BAY11-7082), and of muscarinic receptor antagonists tiotropium bromide, 4-Diphenylacet…

medicine.medical_specialtyIndolesNeutrophilsScopolamine DerivativesBronchiMuscarinic AntagonistsBiologyPharmacologyMaleimideschemistry.chemical_compoundPiperidinesInternal medicineNitrilesMuscarinic acetylcholine receptor M5Muscarinic acetylcholine receptormedicineHumansRNA MessengerSulfonesTiotropium BromideProtein Kinase CCell Line TransformedAcetylcholine receptorFlavonoidsMitogen-Activated Protein Kinase 1PharmacologyMitogen-Activated Protein Kinase 3Gallamine TriethiodideInterleukin-8NF-kappa BMuscarinic acetylcholine receptor M3Epithelial CellsMuscarinic acetylcholine receptor M2PirenzepineMuscarinic acetylcholine receptor M1Receptors MuscarinicAcetylcholineChemotaxis LeukocyteEndocrinologychemistryTelenzepineAcetylcholinemedicine.drugEuropean Journal of Pharmacology
researchProduct

Immunomodulatory and Hematopoietic Effects of Recombinant Human Interleukin-6 in Patients with Advanced Renal Cell Cancer

1996

Interleukin-6 (IL-6) is a cytokine with pleiotropic biologic activities on B cells, T cells, and hematopoietic progenitors. The present study was undertaken to assess pharmacodynamic effects of subcutaneous administration of IL-6 on blood counts, immunologic parameters, and acute-phase reactants. Blood samples were taken from patients with advanced renal cell cancer participating in a phase II trial of recombinant human IL-6. Multiparameter FACS analyses of peripheral blood mononuclear cells were performed using antibodies against CD3, CD4, CD8, HLA-DR, CD56, CD28, CD38, CD19, sIgM, and sIgG. Serum levels of IL-10, soluble CD23 (sCD23), sCD25, IL-1 receptor antagonist protein (IL-1RA), solu…

medicine.medical_specialtyInjections Subcutaneousmedicine.medical_treatmentImmunologyPeripheral blood mononuclear cellCD19chemistry.chemical_compoundImmunophenotypingAdjuvants ImmunologicVirologyInternal medicinemedicineHumansAcute-Phase ReactionCarcinoma Renal CellbiologyInterleukin-6business.industryCD23NeopterinCell BiologyKidney NeoplasmsRecombinant ProteinsBlood Cell CountHematopoiesisHaematopoiesisCytokineEndocrinologychemistryImmunologybiology.proteinbusinessCD8Journal of Interferon & Cytokine Research
researchProduct

Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?

2020

medicine.medical_specialtyInterleukin-13Ocular surface diseasebusiness.industryMEDLINEEczemaDermatologyAtopic dermatitismedicine.diseaseAntibodies Monoclonal HumanizedDupilumabDermatologyDermatitis Atopicdupilumab atopic dermatitis ocular surface diseaseInfectious DiseasesmedicineHumansIn patientbusinessJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

Islet beta-cell apoptosis triggered in vivo by interleukin-1beta is not related to the inducible nitric oxide synthase pathway: evidence for mitochon…

2003

IL-1beta is recognized as an effector cytokine contributing to islet beta-cell destruction during diabetes. We have previously shown in vitro that IL-1beta induces nitric oxide (NO) and beta-cell damage. Here, we show that IL-1beta administration in vivo to Wistar rats transiently increases manganese superoxide dismutase activity, whereas inducible NO synthase is not detected, and the levels of nitrate+nitrate do not change. Moreover, a significant decrease of mitochondrial aconitase, leading to a rise of hydroperoxides, and islet beta-cell apoptosis, involving caspase-3 and -8, is observed. Analysis of adhesion molecules in beta-cells showed that intercellular adhesion molecule-1 is highly…

medicine.medical_specialtyLipid PeroxidesNitric Oxide Synthase Type IIApoptosisBiologyMitochondrionIn Vitro TechniquesAconitaseNitric oxidechemistry.chemical_compoundIslets of LangerhansEndocrinologyIn vivoInternal medicinemedicineAnimalsRats WistarNitritesAconitate HydratasegeographyCaspase 8geography.geographical_feature_categoryNitratesCell adhesion moleculeCaspase 3Superoxide DismutaseIsletIntercellular Adhesion Molecule-1Caspase 9Cell biologyMitochondriaRatsNitric oxide synthaseEndocrinologyBiochemistrychemistryApoptosisCaspasesbiology.proteinNitric Oxide SynthaseInterleukin-1Endocrinology
researchProduct

Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and…

1997

We have tested whether tetracyclines (TETs) are able to protect mice from lipopolysaccharide (LPS)-induced shock, a cytokine-mediated inflammatory reaction. Mice, injected with a single dose of tetracycline base (TETb; 1.5, 10 and 20 mg/kg of body weight) or doxycycline (DOXY; 1.5 mg/kg), were significantly protected from a lethal intraperitoneal injection of LPS (500 micrograms per mouse). TETs acted in early events triggered in response to LSP; in fact, they were no longer significantly protective if injected more than 1 h after the injection of endotoxin. LPS-treated mice protected by TETs showed a significant inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin-1 alpha (IL…

medicine.medical_specialtyLipopolysaccharidemedicine.medical_treatmentIntraperitoneal injectionDown-RegulationAlpha (ethology)SpleenBiologyMicechemistry.chemical_compoundInternal medicinemedicineAnimalsPharmacology (medical)LungAntibacterial agentPharmacologyMice Inbred BALB CNitratesTumor Necrosis Factor-alphaTetracyclineShock SepticEndotoxemiaAnti-Bacterial AgentsNitric oxide synthaseInfectious DiseasesEndocrinologyCytokinemedicine.anatomical_structurechemistryDoxycyclineEnzyme InductionMacrophages Peritonealbiology.proteinCytokinesFemaleTumor necrosis factor alphaNitric Oxide SynthaseInjections IntraperitonealSpleenInterleukin-1Research ArticleAntimicrobial Agents and Chemotherapy
researchProduct

Hepatocellular Hyperplasia, Plasmacytoma Formation, and Extramedullary Hematopoiesis in Interleukin (IL)-6/Soluble IL-6 Receptor Double-Transgenic Mi…

1998

Cytokines interact not only with membrane anchored receptors, but also with specific soluble receptors which circulate in the bloodstream. In general, soluble cytokine receptors such as soluble tumor necrosis factor receptor, soluble interleukin 1 receptor, and soluble interleukin 4 receptor compete with their membrane-bound counterparts for the ligands and therefore act as antagonists. In contrast, soluble receptors for cytokines of the interleukin-6 (IL-6) family complex with their ligands act agonistically. Interestingly, the complex of IL-6 and the soluble interleukin 6 receptor (sIL-6R) activates target cells that do not express the membrane-bound IL-6R and therefore cannot respond to …

medicine.medical_specialtyMice TransgenicInterleukin 1 receptor type IIInterleukin-1 receptorPathology and Forensic MedicineMiceNecrosisInterleukin-4 receptorInternal medicinemedicineAnimalsHumansReceptorInterleukin 6HyperplasiabiologyInterleukin-6Body WeightLiver NeoplasmsInterleukinAnimal ModelsOrgan SizeReceptors Interleukin-6EndocrinologyLiverHematopoiesis ExtramedullaryInterleukin-6 receptorCancer researchbiology.proteinInterleukin 1 receptor type ISpleenPlasmacytomaThe American Journal of Pathology
researchProduct

Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19

2021

Key Points Three-day change in angiopoietin-2 levels predicts COVID-19 in-hospital mortality, whereas the 10-day trend is associated with chronic lung disability. Angiopoietin-2 may play an important pathogenic role in patients with COVID-19, and it could be a target for new treatments.

medicine.medical_specialtyMultivariate analysis20CD34Risk Factors ...030204 cardiovascular system & hematologyGastroenterologyAntiviral AgentsAngiopoietin-203 medical and health sciences0302 clinical medicineRisk FactorsVascular BiologyInternal medicinemedicineHumans030212 general & internal medicineHospital MortalitySurvival rateProportional Hazards ModelsAntiviral AgentLungReceiver operating characteristicbusiness.industryProportional hazards modelSARS-CoV-2Interleukin-6Risk FactorHazard ratioCOVID-19HematologyBiomarker32Confidence intervalCOVID-19 Drug TreatmentHospitalizationSurvival RateAngiopoietin-2; Antiviral Agents; Area Under Curve; Biomarkers; COVID-19; Hospital Mortality; Hospitalization; Humans; Interleukin-6; Proportional Hazards Models; ROC Curve; Risk Factors; SARS-CoV-2; Survival Ratemedicine.anatomical_structureROC CurveArea Under Curvecardiovascular systemProportional Hazards ModelbusinessBiomarkersHuman
researchProduct

The Relationship Between Maximal Exercise-Induced Increases in Serum IL-6, MPO and MMP-9 Concentrations

2012

The aim of this study was to test the hypothesis that exercise would induce inflammatory response characterized by increased pro-inflammatory cytokines - interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α), adhesion molecule, matrix metalloprotease-9 (MMP-9) and myeloperoxidase (MPO) levels. Additional aim was to elucidate the possible source of maximal exercise-induced increase in MMP-9 concentration. To examine our hypothesis, 26 professional male ice hockey players [age 25 ± 1 (mean ± SEM) years; BMI 25.8 ± 0.4 kg/m(2) ] performed an incremental bicycle test until exhaustion, when maximal oxygen consumption was recorded. Venous blood samples were collected 30 min before and 2 min a…

medicine.medical_specialtyNecrosisbiologyChemistryImmunologyDegranulationVO2 maxGeneral MedicineVenous bloodMatrix metalloproteinaseIce hockeyEndocrinologyInternal medicineMyeloperoxidaseImmunologybiology.proteinmedicinemedicine.symptomInterleukin 6Scandinavian Journal of Immunology
researchProduct

Immobilization increases interleukin-6, but not tumour necrosis factor-α, release from the leg during exercise in humans

2013

Data on interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) release during acute exercise are not conclusive, and information is lacking about the impact of physical inactivity. Some studies have shown an increase, but others report no changes in IL-6 and TNF-α release during exercise. We have now studied the temporal relationship of leg IL-6 and TNF-α release before and during isolated two-legged exercise after 14 days of one-leg immobilization (IM) while the other leg served as the control (CON) leg. Fifteen healthy male subjects (mean ± SEM age, 23 ± 1 years; body mass index, 23.6 ± 0.7 kg m(-2); and maximal oxygen uptake, 46.8 ± 1.4 ml kg(-1) min(-1)) performed 45 min of two-legge…

medicine.medical_specialtyNecrosisbiologybusiness.industryFemoral veinVO2 maxGeneral MedicineBlood flowVenous bloodSurgeryEndocrinologyInternal medicinebiology.proteinMedicinemedicine.symptomExercise physiologybusinessInterleukin 6Body mass indexExperimental Physiology
researchProduct